Workflow
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update
Verona PharmaVerona Pharma(US:VRNA) GlobeNewswire News Room·2024-10-21 06:00

Group 1 - Verona Pharma will report its financial results for Q3 2024 on November 4, 2024, and will host a conference call to discuss these results and provide a corporate update [1] - The conference call will take place at 9:00 a.m. EDT / 2:00 p.m. GMT, with participation options available for both U.S. and international callers [1] - A live webcast of the conference call will be accessible on the company's website, and an audio replay will be available for 90 days [1] Group 2 - Verona Pharma is a biopharmaceutical company focused on developing therapies for chronic respiratory diseases with significant unmet medical needs [2] - The company's first commercial product, Ohtuvayre™ (ensifentrine), is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities [2] - Ensifentrine has potential applications in various respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and asthma [2]